Shares of Sana Biotechnology, Inc. (SANA) are set to open sharply lower on Friday, plummeting 5.68% in pre-market trading. This significant drop comes as investors react to a recent analyst report adjusting expectations for the biotechnology company.

The catalyst for this decline appears to be a report from H.C. Wainwright, a well-respected investment bank and research firm. According to the report released early Friday morning, H.C. Wainwright has cut its price target for Sana Biotechnology from $11 to $9, representing a substantial 18% reduction in their valuation outlook for the company.

This downward revision in the price target could signal concerns about Sana Biotechnology's near-term prospects or overall valuation. Investors often view such adjustments from prominent analysts as important indicators of a company's potential performance, which can lead to rapid price movements as seen in this case. As the market digests this new information, it remains to be seen how Sana Biotechnology will respond and whether this pre-market decline will persist throughout the trading day.